

VPA10996/228/001

Finadyne 50 mg/ml Solution for Injection

Variation	Summary	Date
Vet - B33 a)	VNRA - Vet - B33 a) - - Vet - B33 a) - Change in test procedure for the finished product to comply with Ph. Eur.: update of the test procedure to comply with the updated general monograph in the Ph. Eur.	22/07/25
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	23/08/24
Vet - B45	VNRA - Vet - B45 - Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile active substance, starting material, reagent or intermediate, excipient - B45 Changes to the quality part of the dossier: Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	20/10/23
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	21/08/23
Vet - G.I.3 b)	VRA-R - Vet - G.I.3 b) - b) Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon - G.I.3 b) Safety, Efficacy, Pharmacovigilance changes - Change(s) in the SPC, labelling or package	21/08/23

	<p>leaflet intended to implement the outcome of a procedure or recommendations from the competent authority or the Agency concerning risk management measures in pharmacovigilance related to veterinary medicinal products - Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon</p>	
--	---	--